Intrathoracic Progression is Still the Most Dominant Failure Pattern after First-line Chemo-immunotherapy in Extensive-stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to compare the failure patterns before and after the introduction of immunotherapy and to determine the role of thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) treatment. Materials and Methods We retrospectively reviewed 294 patients with ES-SCLC, of which 62.2% underwent chemotherapy alone, 13.3% underwent chemotherapy followed by consolidative TRT (TRT group), and 24.5% underwent chemotherapy with immune checkpoint inhibitor (ICI group). We performed propensity-score matching (PSM) to compare each treatment group. Results The median follow-up duration was 10.4 months. At the first relapse, in the cohort showing objective response, the proportion of cases showing intrathoracic progression was significantly lower in the TRT group (37.8%) than in the chemotherapy-alone (77.2%, p < 0.001) and the ICI (60.3%, p=0.03) groups. Furthermore, in the subgroup analysis, TRT showed benefits related to intrathoracic progression-free survival (PFS) in comparison with ICI in patients with less than two involved extrathoracic sites (p=0.008) or without liver metastasis (p=0.02) or pleural metastasis (p=0.005) at diagnosis. After PSM, the TRT group showed significantly better intrathoracic PFS than both chemotherapy-alone and ICI groups (p < 0.001 and p=0.04, respectively), but showed no significant benefit in terms of PFS and overall survival in comparison with the ICI group (p=0.17 and p=0.31, respectively). Conclusion In ES-SCLC, intrathoracic progression was the most dominant failure pattern after immunotherapy. In the era of chemoimmunotherapy, consolidative TRT can still be considered a useful treatment strategy for locoregional control.
Abstract
Purpose This study aimed to compare the failure patterns before and after the introduction of immunotherapy and to determine the role of thoracic radiotherapy (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) treatment. Materials and Methods We retrospectively reviewed 294 patients with ES-SCLC, of which 62.2% underwent chemotherapy alone, 13.3% underwent chemotherapy followed by consolidative TRT (TRT group), and 24.5% underwent chemotherapy with immune checkpoint inhibitor (ICI group). We performed propensity-score matching (PSM) to compare each treatment group. Results The median follow-up duration was 10.4 months. At the first relapse, in the cohort showing objective response, the proportion of cases showing intrathoracic progression was significantly lower in the TRT group (37.8%) than in the chemotherapy-alone (77.2%, p < 0.001) and the ICI (60.3%, p=0.03) groups. Furthermore, in the subgroup analysis, TRT showed benefits related to intrathoracic progression-free survival (PFS) in comparison with ICI in patients with less than two involved extrathoracic sites (p=0.008) or without liver metastasis (p=0.02) or pleural metastasis (p=0.005) at diagnosis. After PSM, the TRT group showed significantly better intrathoracic PFS than both chemotherapy-alone and ICI groups (p < 0.001 and p=0.04, respectively), but showed no significant benefit in terms of PFS and overall survival in comparison with the ICI group (p=0.17 and p=0.31, respectively). Conclusion In ES-SCLC, intrathoracic progression was the most dominant failure pattern after immunotherapy. In the era of chemoimmunotherapy, consolidative TRT can still be considered a useful treatment strategy for locoregional control.
참고문헌 (28)
- Tariq S, "Update 2021 : management of small cell lung cancer", Lung, 199, pp.579~587 (2021)
- Stahel R, "1st ESMO Consensus Conference in lung cancer; Lugano 2010 : small-cell lung cancer", Ann Oncol, 22, pp.1973~1980 (2011)
- Farago AF, "Current standards for clinical management of small cell lung cancer", Transl Lung Cancer Res, 7, pp.69~79 (2018)
- Socinski MA, "Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer", J Clin Oncol, 27, pp.4787~4792 (2009)
- Zhang X, "Consolidative thoracic radiotherapy for extensive stage small cell lung cancer", Oncotarget, 8, pp.22251~22261 (2017)
- Jeremic B, "Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer : a randomized study", J Clin Oncol, 17, pp.2092~2099 (1999)
- Slotman BJ, "Use of thoracic radiotherapy for extensive stage small-cell lung cancer : a phase 3 randomised controlled trial", Lancet, 385, pp.36~42 (2015)
- Palma DA, "Thoracic radiotherapy for extensive stage small-cell lung cancer : a meta-analysis", Clin Lung Cancer, 17, pp.239~244 (2016)
- Gore EM, "Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer(ED SCLC) : NRG Oncology RTOG 0937", J Thorac Oncol, 12, pp.1561~1570 (2017)
- Rathod S, "Role of thoracic consolidation radiation in extensive stage small cell lung cancer : a systematic review and meta-analysis of randomised controlled trials", Eur J Cancer, 110, pp.110~119 (2019)
- Li AM, "Role of thoracic radiotherapy in extensive stage small cell lung cancer : a systemic review and meta-analysis", Ann Transl Med, 9, pp.299~ (2021)
- Horn L, "First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer", N Engl J Med, 379, pp.2220~2229 (2018)
- Paz-Ares L, "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN) : a randomised, controlled, open-label, phase 3 trial", Lancet, 394, pp.1929~1939 (2019)
- Liu SV, "Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide(IMpower133)", J Clin Oncol, 39, pp.619~630 (2021)
- Simone CB 2nd, "Radiation therapy for small cell lung cancer : an ASTRO clinical practice guideline", Pract Radiat Oncol, 10, pp.158~173 (2020)
- "NCCN clinical practice guidelines in oncology. Small cell lung cancer (version 2. 2023)", National Comprehensive Cancer Network, ~ (2023)
- Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Ihde DC, "Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer", J Clin Oncol, 12, pp.2022~2034 (1994)
- Yavas G, "Thoracic radiotherapy for extensive-stage small-cell lung cancer : what is the optimal dose and timing?", J Radiat Oncol, 8, pp.251~258 (2019)
- Slotman BJ, "Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy : a secondary analysis of the Phase III CREST trial", Lung Cancer, 108, pp.150~153 (2017)
- Antonia SJ, "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer", N Engl J Med, 377, pp.1919~1929 (2017)
- Antonia SJ, "Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC", N Engl J Med, 379, pp.2342~2350 (2018)
- Galuba JM, "P63.10 Safety of simultaneously performed radiotherapy in patients with small-cell lung cancer undergoing atezolizumab treatment", J Thorac Oncol, 16, pp.S1186~ (2021)
- Diamond BH, "Consolidative thoracic radiation therapy after first-line chemotherapy and immunotherapy in extensive-stage small cell lung cancer : a multi-institutional case series", Adv Radiat Oncol, 7, pp.100883~ (2022)
- Deng L, "Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice", J Clin Invest, 124, pp.687~695 (2014)
- Nesbit EG, "What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?", Transl Lung Cancer Res, 8, pp.S153~S162 (2019)
- "Testing the addition of radiation therapy to the usual immune therapy treatment (atezolizumab) for extensive stage small cell lung cancer, the RAPTOR trial. ClinicalTrials.gov ID. NCT04402788" (2023)[URL]
- Bozorgmehr F, "Protocol of the TREASURE study : thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease-a randomized, open-label, multicenter phase II trial", BMC Cancer, 22, pp.1011~ (2022)